0R3M.LSE Vivoryon Therapeutics N.V.

Healthcare Biotechnology London Exchange
2.08 EUR
Close of Aug 12, 2026
0.7600 1.65
Market cap
EUR 17.0M
P/E
-
P/B
-
ROE
-865.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0R3M.LSE undervalued?

Graham number

The Graham number of Vivoryon Therapeutics N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vivoryon Therapeutics N.V. fundamental analysis

No fundamental analysis for Vivoryon Therapeutics N.V. yet.

Vivoryon Therapeutics N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company i…

Full company profile